BR112016019286A2 - anticorpos do componente c5 do complemento - Google Patents

anticorpos do componente c5 do complemento

Info

Publication number
BR112016019286A2
BR112016019286A2 BR112016019286A BR112016019286A BR112016019286A2 BR 112016019286 A2 BR112016019286 A2 BR 112016019286A2 BR 112016019286 A BR112016019286 A BR 112016019286A BR 112016019286 A BR112016019286 A BR 112016019286A BR 112016019286 A2 BR112016019286 A2 BR 112016019286A2
Authority
BR
Brazil
Prior art keywords
antibodies
complement component
disclosure relates
complement
diagnosing
Prior art date
Application number
BR112016019286A
Other languages
English (en)
Other versions
BR112016019286B1 (pt
Inventor
Guu Jason
Desjarlais John
Bernett Matthew
C Baciu Peter
Muchhal Umesh
Liang Yanbin
Original Assignee
Allergan Inc
Xencor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc, Xencor Inc filed Critical Allergan Inc
Priority claimed from PCT/US2015/016699 external-priority patent/WO2015127134A2/en
Publication of BR112016019286A2 publication Critical patent/BR112016019286A2/pt
Publication of BR112016019286B1 publication Critical patent/BR112016019286B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

a presente divulgação refere-se a anticorpos e polinucleotídeos que codificam os mesmos, que podem ser usados para prevenir, controlar, ou reduzir a atividade da via do complemento. além disso, a divulgação é direcionada a composições e métodos para diagnosticar e tratar doenças mediadas ou que envolvam o c5 do complemento. especificamente, a divulgação refere-se a anticorpos de c5.
BR112016019286-9A 2014-02-26 2015-02-19 Anticorpo anti-c5 BR112016019286B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461944943P 2014-02-26 2014-02-26
US61/944,943 2014-02-26
PCT/US2015/016699 WO2015127134A2 (en) 2014-02-20 2015-02-19 Complement component c5 antibodies

Publications (2)

Publication Number Publication Date
BR112016019286A2 true BR112016019286A2 (pt) 2017-10-10
BR112016019286B1 BR112016019286B1 (pt) 2024-02-20

Family

ID=62620470

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016019286-9A BR112016019286B1 (pt) 2014-02-26 2015-02-19 Anticorpo anti-c5

Country Status (7)

Country Link
KR (2) KR20220164083A (pt)
CN (2) CN114716544A (pt)
BR (1) BR112016019286B1 (pt)
DK (1) DK3107935T3 (pt)
ES (1) ES2824262T3 (pt)
HU (1) HUE050921T2 (pt)
IL (1) IL304203A (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111171149B (zh) * 2020-02-23 2021-09-07 北京康普美特创新医药科技有限责任公司 一种抗补体c5分子的人源化单链抗体及其应用
CN111234016B (zh) * 2020-02-23 2021-09-07 北京康普美特创新医药科技有限责任公司 一种抗补体c5分子的全人源单克隆抗体及应用
CN113754763B (zh) * 2020-06-05 2024-03-08 天辰生物医药(苏州)有限公司 分离的抗原结合蛋白及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
JP2008520242A (ja) * 2004-11-18 2008-06-19 イェール ユニバーシティ 視覚障害を処置するための方法および組成物
ZA200707420B (en) * 2005-02-14 2009-04-29 Univ Iowa Res Found Methods and reagents for treatment and diagnosis of age-related macular degeneration
CN101443050A (zh) * 2006-03-08 2009-05-27 阿切埃米克斯有限公司 治疗视觉失调中使用的补体结合适体和抗-c5药物
KR20150029002A (ko) * 2007-06-07 2015-03-17 제넨테크, 인크. 보체-관련 장애의 예방 및 치료를 위한 Ｃ３ｂ 항체 및 방법
JP5815403B2 (ja) * 2008-08-05 2015-11-17 ノバルティス アーゲー 補体タンパク質ｃ５を標的とする抗体に関する組成物および方法
BRPI0921237A2 (pt) * 2008-11-10 2015-09-22 Alexion Pharma Inc métodos e composições para o tratamento de distúrbios associados ao complemento
TW201241008A (en) * 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5

Also Published As

Publication number Publication date
CN107207585A (zh) 2017-09-26
HUE050921T2 (hu) 2021-01-28
CN107207585B (zh) 2021-12-21
DK3107935T3 (da) 2020-09-21
KR20230149865A (ko) 2023-10-27
ES2824262T3 (es) 2021-05-11
CN114716544A (zh) 2022-07-08
BR112016019286B1 (pt) 2024-02-20
IL304203A (en) 2023-09-01
KR20220164083A (ko) 2022-12-12

Similar Documents

Publication Publication Date Title
BR112016019825A2 (pt) anticorpos do fator bb do complemento
BR112018004620A2 (pt) moduladores da expressão de kras
BR112017017286A2 (pt) protease de cisteína
BR112018008867A2 (pt) anticorpos que se ligam especificamente a pd-1 e seus usos
BR112017017284A2 (pt) protease de cisteína
CU20160185A7 (es) Compuestos de heteroarilo para la inhibición de cinasa
BR112016025470A2 (pt) ?hdl terapêutico?
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
BR112016024780A2 (pt) composições e métodos relacionados com construtos de fc manipulados
BR112017006664A2 (pt) terapias de combinação
MX2017014191A (es) Metodos de tratamiento de una enfermedad neurodegenerativa.
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
BR112016016436A2 (pt) moléculas de anticorpo para tim-3 e usos das mesmas
BR112015029969A2 (pt) tratamento de câncer usando moduladores de isoformas quinase pi3
BR112017005517A2 (pt) anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes
BR112016007467A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112018013522A2 (pt) compostos inibidores de metaloenzima
BR112016030690A2 (pt) moduladores do receptor de arila e métodos de fabricar e usar os mesmos
WO2015127134A3 (en) Complement component c5 antibodies
BR102015017380A2 (pt) dispositivo para a reticulação do tecido do olho, e, composição farmacêutica
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
BR112017008714A2 (pt) inibidores de bromodomínio
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
BR112015017241A2 (pt) doadores de nitroxil com índice terapêutico melhorado

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/02/2015, OBSERVADAS AS CONDICOES LEGAIS